All In Biotech

Free tool

FAERS Monitor: Fosaprepitant Dimeglumine

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 210064 or its brand name (Fosaprepitant Dimeglumine, Fosaprepitant Dimeglumine). Reports on generic versions are filed under their own applications.

Reports

2,520

Serious

2,230

88% of reports

Hospitalization

1,262

Death reported

510

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • dyspnoea426
  • infusion related reaction360
  • alopecia335
  • fatigue315
  • pyrexia304
  • hypersensitivity300
  • nausea283
  • arthralgia276
  • glossodynia271
  • pruritus271
  • helicobacter infection270
  • confusional state269
  • duodenal ulcer perforation269
  • pain269
  • stomatitis267

Reports by year received

View as table
YearReports
20081
20093
20102
20116
201294
201364
201479
201573
201671
201777
2018142
2019134
2020155
2021199
2022274
2023217
2024285
2025379
2026265

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,639 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
duodenal ulcer perforationSignal269313.2279.180,415
helicobacter infectionSignal270225.1200.858,469
glossodyniaSignal271102.391.326,775
infusion related reactionSignal36045.641.415,613
stomatitisSignal26736.932.99,276
alopeciaSignal33514.312.94,149
confusional stateSignal26913.912.43,231
hypersensitivitySignal30013.512.13,488
pyrexiaSignal3047.36.61,684
dyspnoeaSignal4266.35.81,939
pruritusSignal2715.95.31,115
arthralgiaSignal2765.55.01,043
painSignal2693.73.3532
fatigueSignal3153.43.0545
nauseaSignal2833.02.7386

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.